With Positive Phase II Data on HCV Drug, Santaris Aims for Another Clinical Trial by the Summer | GenomeWeb

Having just released phase IIa data demonstrating the antiviral activity of its microRNA-targeting hepatitis C treatment miravirsen, Santaris Pharma is preparing to begin within a few months another phase II study that will examine the drug in combination with direct-acting antiviral agents, a company official said.

“Miravirsen is certainly doing what it says on the bottle … [demonstrating] a high barrier to resistance [with] good saturation and distribution within the liver,” Santaris CMO Michael Hodges told Gene Silencing News this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.